Review article: Alcohol and gut microbiota - The possible role of gut microbiota modulation in the treatment of alcoholic liver disease

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 10, 2015, Pages 917-927

  Vassallo, G ^a   Mirijello, A ^a   Ferrulli, A ^a   Antonelli, M ^a   Landolfi, R ^a   Gasbarrini, A ^a   Addolorato, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; BACTERIAL TRANSLOCATION; CLINICAL STUDY; DISEASE ASSOCIATION; DYSBIOSIS; HUMAN; INTESTINE FLORA; METABOLOMICS; METAGENOMICS; MICROBIOME; NONHUMAN; POPULATION ABUNDANCE; PRIORITY JOURNAL; PYROSEQUENCING; REVIEW; TRANSCRIPTOMICS; ANIMAL; GASTROINTESTINAL TRACT; LIVER DISEASES, ALCOHOLIC; MICROBIOLOGY; MICROFLORA;

PREBIOTIC AGENT; PROBIOTIC AGENT;

ANIMALS; GASTROINTESTINAL TRACT; HUMANS; LIVER DISEASES, ALCOHOLIC; MICROBIOTA; PREBIOTICS; PROBIOTICS;

EID: 84927772360     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13164     Document Type: Review

References (74)

1. World Health Organization Global Status Report On Alcohol. Geneva, Switzerland: World Health Organization, 2004.
2. Tilg H, Day CP,. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 24-34.
3. O'Shea RS, Dasarathy S, McCullough AJ,. Alcoholic liver disease. Am J Gastroenterol 2010; 105: 14-32.
4. Bode JC, Parlesak A, Bode C,. Gut-derived bacterial toxins (endotoxin) and alcoholic liver disease. In:, Agarwal DP, Seitz HK, eds. Alcohol in Health and Disease. New York, Basel: Marcel Dekker, 2001; 369-86.
5. Salaspuro M,. Alcohol metabolism by gut flora. Metabolic, pathogenetic, and clinical implications. In:, Agarwal DP, Seitz HK, eds. Alcohol in Health and Disease. New York, Basel: Marcel Dekker, 2001; 67-85.
6. Bode C, Bode JC,. Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol 2003; 17: 575-92.
7. Lucey MR, Mathurin P, Morgan TR,. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758-69.
8. Goel A, Gupta M, Aggarwal R,. Gut microbiota and liver disease. J Gastroenterol Hepatol 2014; 29: 1139-48.
9. Guarner F, Malagelada JR,. Gut flora in health and disease. Lancet 2003; 361: 512-9.
10. O'Keefe SJ,. Nutrition and colonic health: the critical role of the microbiota. Curr Opin Gastroenterol 2008; 24: 51-8.
11. Gill SR, Pop M, Deboy RT, et al,. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-9.
12. Lopetuso LR, Scaldaferri F, Petito V, Gasbarrini A,. Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog 2013; 5: 23.
13. Frank DN, St Amand AL, Feldman RA, et al,. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-5.
14. Purchiaroni F, Tortora A, Gabrielli M, et al,. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci 2013; 17: 323-33.
15. Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A,. Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota. World J Gastroenterol 2012; 18: 6693-700.
16. Angelakis E, Armougom F, Million M, Raoult D,. The relationship between gut microbiota and weight gain in humans. Future Microbiol 2012; 7: 91-109.
17. Allen CA, Torres AG,. Host-microbe communication within the GI tract. Adv Exp Med Biol 2008; 635: 93-101.
18. Hill DA, Hoffmann C, Abt MC, et al,. Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. Mucosal Immunol 2010; 3: 148-58.
19. Mutlu E, Keshavarzian A, Engen P, et al,. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 2009; 33: 1836-46.
20. Yan AW, Fouts DE, Brandl J, et al,. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53: 96-105.
21. Derrien M, Collado MC, Ben-Amor K, Salminen S, de Vos WM,. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Appl Environ Microbiol 2008; 74: 1646-8.
22. Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S,. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol 2007; 73: 7767-70.
23. Yan AW, Schnabl B,. Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World J Hepatol 2012; 4: 110-8.
24. Nanji AA, Khettry U, Sadrzadeh SM,. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994; 205: 243-7.
25. Bull-Otterson L, Feng W, Kirpich I, et al,. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS ONE 2013; 8: e53028.
26. Campos Canesso M., Lacerda Queiroz N., Marcantonio C., et al,. Comparing the effects of acute alcohol consumption in germ-free and conventional mice: the role of the gut microbiota. BMC Microbiol 2014; 14: 240.
27. Bode JC, Bode C, Heidelbach R, Dürr HK, Martini GA,. Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology 1984; 31: 30-4.
28. Bode C, Kolepke R, Schäfer K, Bode JC,. Breath hydrogen excretion in patients with alcoholic liver disease evidence of small intestinal bacterial overgrowth. Z Gastroenterol 1993; 31: 3-7.
29. Hauge T, Persson J, Danielsson D,. Mucosal bacterial growth in the upper gastrointestinal tract in alcoholics (heavy drinkers). Digestion 1997; 58: 591-5.
30. Hauge T, Persson J, Kjerstadius T,. Helicobacter pylori, active chronic antral gastritis, and gastrointestinal symptoms in alcoholics. Alcohol Clin Exp Res 1994; 18: 886-8.
31. Buzás GM,. Prevalence of Helicobacter pylori, correlations between alcohol consumption and gastroduodenal damage. Orv Hetil 1997; 138: 2791-5.
32. Casafont Morencos F, de las Heras Castaño G, Martín Ramos L, et al,. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1996; 41: 552-6.
33. Gabbard SL, Lacy BE, Levine GM, et al,. The impact of alcohol consumption and cholecystectomy on small intestinal bacterial overgrowth. Dig Dis Sci 2014; 59: 638-44.
34. Mutlu EA, Gillevet PM, Rangwala H, et al,. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012; 302: G966-78.
35. Chen Y, Yang F, Lu H, et al,. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011; 54: 562-72.
36. Hartmann P, Chen WC, Schnabl B,. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol 2012; 3: 402.
37. Bhonchal S, Nain CK, Taneja N, et al,. Modification of small bowel microflora in chronic alcoholics with alcoholic liver disease. Trop Gastroenterol 2007; 28: 64-6.
38. Addolorato G, Montalto M, Capristo E, et al,. Influence of alcohol on gastrointestinal motility: lactulose breath hydrogen testing in orocecal transit time in chronic alcoholics, social drinkers and teetotaler subjects. Hepatogastroenterology 1997; 44: 1076-81.
39. Sibley D, Jerrells TR,. Alcohol consumption by C57BL/6 mice is associated with depletion of lymphoid cells from the gut-associated lymphoid tissues and altered resistance to oral infections with Salmonella typhimurium. J Infect Dis 2000; 182: 482-9.
40. Choudhry MA, Fazal N, Goto M, Gamelli RL, Sayeed MM,. Gut-associated lymphoid T cell suppression enhances bacterial translocation in alcohol and burn injury. Am J Physiol Gastrointest Liver Physiol 2002; 282: G937-47.
41. Kavanaugh MJ, Clark C, Goto M, et al,. Effect of acute alcohol ingestion prior to burn injury on intestinal bacterial growth and barrier function. Burns 2005; 31: 290-6.
42. Kolida S, Gibson GR,. Prebiotic capacity of inulin-type fructans. J Nutr 2007; 137: 2503S-6S.
43. Curtis BJ, Zahs A, Kovacs EJ,. Epigenetic targets for reversing immune defects caused by alcohol exposure. Alcohol Res 2013; 35: 97-113.
44. Park BJ, Lee YJ, Lee HR,. Chronic liver inflammation: clinical implications beyond alcoholic liver disease. World J Gastroenterol 2014; 20: 2168-75.
45. Mukhopadhya I, Hansen R, El-Omar EM, Hold GL,. IBD-what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol 2012; 9: 219-3.
46. Fukui H, Brauner B, Bode JC, Bode C,. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991; 12: 162-9.
47. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG,. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108: 218-24.
48. Parlesak A, Schafer C, Schutz T, Bode JC, Bode C,. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000; 32: 742-7.
49. Urbaschek R, McCuskey RS, Rudi V, et al,. Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. Alcohol Clin Exp Res 2001; 25: 261-8.
50. Trebicka J, Krag A, Gansweid S, et al,. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol 2011; 23: 1218-25.
51. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG,. Toll-like receptor 4 is involved in the mechanism of early alcohol- induced liver injury in mice. Hepatology 2001; 34: 101-8.
52. Addolorato G, Mirijello A, Leggio L, Ferrulli A, Landolfi R,. Management of alcohol dependence in patients with liver disease. CNS Drugs 2013; 27: 287-99.
53. Gao B, Bataller R,. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-85.
54. Kirpich IA, Solovieva NV, Leikhter SN, et al,. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008; 42: 675-82.
55. Loguercio C, Federico A, Tuccillo C, et al,. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-3.
56. Madrid AM, Hurtado C, Venegas M, Cumsille F, Defilippi C,. Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol 2001; 96: 1251-5.
57. Leber B, Spindelboeck W, Stadlbauer V,. Infectious complications of acute and chronic liver disease. Semin Respir Crit Care Med 2012; 33: 80-95.
58. Terg R, Fassio E, Guevara M, et al,. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008; 48: 774-9.
59. Ginés P, Rimola A, Planas R, et al,. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12 (4 Pt 1): 716-24.
60. Bass NM, Mullen KD, Sanyal AG, et al,. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-81.
61. Campillo B, Dupeyron C, Richardet JP, Mangeney N, Leluan G,. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998; 26: 1066-70.
62. Fernández J, Navasa M, Gõmez J, et al,. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35: 140-8.
63. Rivkin A, Gim S,. Rifaximin: new therapeutic indication and future directions. Clin Ther 2001; 33: 812-27.
64. Kalambokis GN, Mouzaki A, Rodi M, et al,. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 2012; 10: 815-8.
65. Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV,. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liver Int 2012; 32: 467-75.
66. Vlachogiannakos J, Viazis N, Vasianopoulou P, et al,. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013; 28: 450-5.
67. Stadlbauer V, Mookerjee RP, Hodges S, et al,. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008; 48: 945-51.
68. Lata J, Novotný I, Príbramská V, et al,. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007; 19: 1111-3.
69. Besselink MG, van Santvoort HC, Buskens E, et al,. Probiotic prophylaxis in patients with predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Ned Tijdschr Geneeskd 2008; 152: 685-96.
70. Muñoz P, Bouza E, Cuenca-Estrella M, et al,. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40: 1625-34.
71. Watanabe A, Sakai T, Sato S, et al,. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26: 1410-4.
72. Tang Y, Forsyth CB, Banan A, Fields JZ, Keshavarzian A,. Oats supplementation prevents alcohol-induced gut leakiness in rats by preventing alcohol-induced oxidative tissue damage. J Pharmacol Exp Ther 2009; 329: 952-8.
73. Marotta F, Barreto R, Wu CC, et al,. Experimental acute alcohol pancreatitis-related liver damage and endotoxemia: synbiotics but not metronidazole have a protective effect. Chin J Dig Dis 2005; 6: 193-7.
74. Riordan SM, Skinner NA, McIver CJ, et al,. Synbiotic-associated improvement in liver function in cirrhotic patients: relation to changes in circulating cytokine messenger RNA and protein levels. Microb Ecol Health Dis 2007; 19: 7-16.